Skip to search formSkip to main contentSkip to account menu

indium In 111 ibritumomab tiuxetan

Known as: In 111 Ibritumomab Tiuxetan, In111 ibritumomab tiuxetan, Indium In-111 Ibritumomab Tiuxetan 
A radiolabeled monoclonal antibody that is used to detect certain types of B-cell non-Hodgkin lymphoma and is being studied in the detection of other… 
National Institutes of Health

Related topics

Related topics

2 relations
IDEC-In2B8/rituximabIDEC-In2B8/rituximab/yttrium Y 90 ibritumomab tiuxetan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
This manuscript reviews current advances in the use of radioimmunotherapy (RIT) for the treatment of B-cell non-Hodgkin’s… 
Review
2012
Review
2012
Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphoma
Antibody-based therapeutic approaches have had a significant impact in the treatment of non-Hodgkin’s lymphoma (NHL). Rituximab’s… 
Highly Cited
2012
Highly Cited
2012
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET
PurposePositron emission tomography (PET) with 89Zr-ibritumomab tiuxetan can be used to monitor biodistribution of 90Y… 
Review
2012
Review
2012
Radioimmunotherapy for B-cell non-hodgkin lymphomas.
BACKGROUND Radioimmunotherapy (RIT) is a safe and effective therapeutic option for patients with indolent B-cell non-Hodgkin… 
Highly Cited
2010
Highly Cited
2010
Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients
Purpose: This study aimed to evaluate the efficacy and safety of the treatment with 90Y-ibritumomab tiuxetan following a short… 
2009
2009
Japanese phase II study of 90Y‐ibritumomab tiuxetan in patients with relapsed or refractory indolent B‐cell lymphoma
There is no data about the efficacy and safety of radioimmunotherapy with 90Y‐ibritumomab tiuxetan in patients with relapsed or… 
Highly Cited
2007
Highly Cited
2007
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
We retrospectively evaluated our single-center clinical experience with 90Y-ibritumomab tiuxetan and 131I-tositumomab for therapy… 
Review
2005
Review
2005
The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry.
UNLABELLED The ibritumomab tiuxetan therapeutic regimen consists of a dose of rituximab, 250 mg/m(2), followed by (111)In… 
Highly Cited
2004
Highly Cited
2004
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
We report updated time-to-event variables of a phase III randomized study comparing yttrium 90-labeled ibritumomab with rituximab… 
2004
2004
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase…
Presently, there is no standard second-line regimen for patients (pts) with diffuse large B-cell lymphoma (DLBCL) who cannot… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)